Valuation: BioNTech SE

Market Cap 20.65B 23.51B 19.28B 17.69B 33.12B 2,251B 33.94B 229B 89.41B 1,114B 88.25B 86.34B 3,851B P/E 2026 *
-18.6x
P/E 2027 * -17.9x
Enterprise Value 9.8B 11.16B 9.15B 8.4B 15.72B 1,069B 16.11B 109B 42.44B 529B 41.89B 40.98B 1,828B EV / Sales 2026 *
4.52x
EV / Sales 2027 * 5.1x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.54%
1 week+1.22%
Current month-0.11%
1 month-1.39%
3 months-8.49%
6 months-20.40%
Current year-2.36%
1 week 88.5
Extreme 88.5
94.38
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/5/26 Free

Executive/Senior Manager

22,655 0.0094%
12/5/26 Free

Chief Operating Officer

22,655 0.0094%
12/5/26 Free

Chief Financial Officer

33,982 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%+1.22%-16.62%-13.47% 23.51B
-1.73%-4.37%+45.68%+66.78% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
-0.97%-3.30%-1.79%+383.00% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-0.79%-2.60%+26.72%-33.46% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
+1.50%+1.72%+85.76%+166.11% 12.61B
Average -1.12%-1.29%+42.00%+164.48% 25.01B
Weighted average by Cap. -0.59%-0.56%+35.19%+129.44%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 2.02B 1.86B 3.48B 236B 3.56B 24B 9.38B 117B 9.26B 9.06B 404B 2.23B 2.54B 2.08B 1.91B 3.58B 243B 3.67B 24.69B 9.66B 120B 9.53B 9.32B 416B
Net income -1.04B -1.19B -975M -895M -1.67B -114B -1.72B -11.56B -4.52B -56.33B -4.46B -4.37B -195B -1.16B -1.33B -1.09B -998M -1.87B -127B -1.91B -12.89B -5.04B -62.82B -4.98B -4.87B -217B
Net Debt -10.85B -12.35B -10.13B -9.29B -17.4B -1,183B -17.83B -120B -46.97B -585B -46.36B -45.35B -2,023B -9.28B -10.56B -8.66B -7.95B -14.88B -1,012B -15.25B -103B -40.18B -501B -39.66B -38.8B -1,731B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
29/07/26 USD 92.95 +0.54% 740,136
28/07/26 USD 92.45 +1.49% 679,283
27/07/26 USD 91.09 +1.97% 687,342
24/07/26 USD 89.33 -2.97% 886,104
23/07/26 USD 92.06 +0.25% 539,216
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
81.68EUR
Average target price
107.04EUR
Spread / Average Target
+31.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock